WallStSmart

BrightSpring Health Services, Inc. Common Stock (BTSG)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 405% more annual revenue ($65.18B vs $12.91B). LLY leads profitability with a 31.7% profit margin vs 1.5%. LLY trades at a lower P/E of 38.5x. LLY earns a higher WallStSmart Score of 78/100 (B+).

BTSG

Buy

54

out of 100

Grade: C-

Growth: 8.7Profit: 4.5Value: 5.7Quality: 6.0
Piotroski: 5/9Altman Z: 2.62

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BTSGUndervalued (+86.0%)

Margin of Safety

+86.0%

Fair Value

$286.73

Current Price

$48.15

$238.58 discount

UndervaluedFair: $286.73Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTSG2 strengths · Avg: 9.0/10
EPS GrowthGrowth
338.3%10/10

Earnings expanding 338.3% YoY

Revenue GrowthGrowth
29.3%8/10

Revenue surging 29.3% year-over-year

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$789.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

EPS GrowthGrowth
51.4%10/10

Earnings expanding 51.4% YoY

Areas to Watch

BTSG4 concerns · Avg: 3.0/10
Return on EquityProfitability
5.9%3/10

ROE of 5.9% — below average capital efficiency

Profit MarginProfitability
1.5%3/10

1.5% margin — thin

Operating MarginProfitability
3.0%3/10

Operating margin of 3.0%

Debt/EquityHealth
1.483/10

Elevated debt levels

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
38.5x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
28.7x2/10

Trading at 28.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : BTSG

The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.

Bear Case : BTSG

The primary concerns for BTSG are Return on Equity, Profit Margin, Operating Margin. A P/E of 100.3x leaves little room for execution misses. Thin 1.5% margins leave little buffer for downturns.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Key Dynamics to Monitor

BTSG carries more volatility with a beta of 2.05 — expect wider price swings.

LLY is growing revenue faster at 42.6% — sustainability is the question.

LLY generates stronger free cash flow (678M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (78/100 vs 54/100), backed by strong 31.7% margins and 42.6% revenue growth. BTSG offers better value entry with a 86.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BrightSpring Health Services, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

BrightSpring Health Services, Inc. (BTSG) is a prominent provider of home and community-based health services, dedicated to addressing the complex needs of a varied patient population, including those with intellectual and developmental disabilities and individuals requiring rehabilitation. The company focuses on delivering personalized care solutions facilitated by a skilled workforce, which enhances patient outcomes and quality of life. With its strategic investments in innovative technology and a firm commitment to quality, BrightSpring is well-equipped to excel in the expanding value-based care market and to effectively navigate the evolving healthcare landscape.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?